恩考芬尼、比美替尼和西妥昔单抗用于BRAF V600E突变型结直肠癌。回复。 - Suppr

Suppr

超能文献

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. Reply.

作者信息

Kopetz Scott, Grothey Axel, Tabernero Josep

机构信息

University of Texas M.D. Anderson Cancer Center, Houston, TX.

West Cancer Center and Research Institute, Germantown, TN.

出版信息

N Engl J Med. 2020 Feb 27;382(9):877-878. doi: 10.1056/NEJMc1915676.

DOI:10.1056/NEJMc1915676

PMID:32101678

Abstract

摘要

相似文献

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. Reply.恩考芬尼、比美替尼和西妥昔单抗用于BRAF V600E突变型结直肠癌。回复。

N Engl J Med. 2020 Feb 27;382(9):877-878. doi: 10.1056/NEJMc1915676.

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.恩考芬尼、比美替尼和西妥昔单抗用于BRAF V600E突变型结直肠癌的治疗

N Engl J Med. 2020 Feb 27;382(9):876. doi: 10.1056/NEJMc1915676.

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.恩考芬尼、比美替尼和西妥昔单抗用于BRAF V600E突变型结直肠癌的治疗

N Engl J Med. 2020 Feb 27;382(9):876. doi: 10.1056/NEJMc1915676.

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.恩考芬尼、比美替尼和西妥昔单抗用于BRAF V600E突变型结直肠癌的治疗

N Engl J Med. 2020 Feb 27;382(9):876-877. doi: 10.1056/NEJMc1915676.

Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study.encorafenib/西妥昔单抗联合或不联合 binimetinib 治疗 BRAF V600E 突变型转移性结直肠癌患者的疗效和安全性：一项 ACEO 真实世界多中心研究。

ESMO Open. 2024 Sep;9(9):103696. doi: 10.1016/j.esmoop.2024.103696. Epub 2024 Sep 9.

V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab.采用恩考芬尼、比美替尼和西妥昔单抗成功治疗的伴有中枢神经系统转移的V600E突变型结直肠癌。

CNS Oncol. 2024 Jun 6;13(1):2347824. doi: 10.1080/20450907.2024.2347824. Epub 2024 May 22.

Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.恩考芬尼联合西妥昔单抗和/或比美替尼治疗 BRAF V600E 突变转移性结直肠癌患者：来自意大利多中心经验的真实世界数据。

ESMO Open. 2022 Jun;7(3):100506. doi: 10.1016/j.esmoop.2022.100506. Epub 2022 Jun 10.

BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer.BIG BANG 研究（EPOC1703）：一项多中心、概念验证、Ⅱ期研究，评估 binimetinib、encorafenib 和 cetuximab 联合治疗方案在 BRAF 非 V600E 突变型转移性结直肠癌患者中的疗效和安全性。

ESMO Open. 2020;5(1):e000624. doi: 10.1136/esmoopen-2019-000624. Epub 2020 Sep 30.

Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA.美国 BRAF V600E 突变型转移性结直肠癌中恩考芬尼、比尼替尼和西妥昔单抗的成本效益分析。

Adv Ther. 2021 Mar;38(3):1650-1659. doi: 10.1007/s12325-021-01627-8. Epub 2021 Feb 10.

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.伴有或不伴有 binimetinib 治疗的 encorafenib 联合 cetuximab 治疗 BRAF V600E 突变型转移性结直肠癌患者的生活质量：来自 BEACON CRC 的患者报告结局。

ESMO Open. 2022 Jun;7(3):100477. doi: 10.1016/j.esmoop.2022.100477. Epub 2022 May 30.

引用本文的文献

Molecular profiling and patient selection for the multimodal approaches for patients with resectable colorectal liver metastases.可切除性结直肠癌肝转移患者多模式治疗方法的分子特征分析与患者选择

Hepatobiliary Surg Nutr. 2024 Apr 3;13(2):273-292. doi: 10.21037/hbsn-22-616. Epub 2023 Jul 11.

Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An -- Approach.食物和质子泵抑制剂对恩考芬尼吸收的影响：一种 -- 方法。

Mol Pharm. 2023 May 1;20(5):2589-2599. doi: 10.1021/acs.molpharmaceut.3c00016. Epub 2023 Apr 10.

A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells.一种改良的波动测试框架刻画了结直肠癌细胞持久细胞的群体动力学和突变率。

Nat Genet. 2022 Jul;54(7):976-984. doi: 10.1038/s41588-022-01105-z. Epub 2022 Jul 11.

Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy.结直肠癌异质性及其对精准医学和治疗效果的影响。

Biomedicines. 2022 Apr 30;10(5):1035. doi: 10.3390/biomedicines10051035.

[Influence of molecular markers on oncological surgery of colorectal cancer].[分子标志物对结直肠癌肿瘤外科手术的影响]

Chirurg. 2021 Nov;92(11):986-995. doi: 10.1007/s00104-021-01486-7. Epub 2021 Aug 27.

Global colorectal cancer burden in 2020 and projections to 2040.2020年全球结直肠癌负担及到2040年的预测。

Transl Oncol. 2021 Oct;14(10):101174. doi: 10.1016/j.tranon.2021.101174. Epub 2021 Jul 6.

Early response in phosphorylation of ribosomal protein S6 is associated with sensitivity to trametinib in colorectal cancer cells.核糖体蛋白 S6 磷酸化的早期反应与结直肠癌细胞对曲美替尼的敏感性相关。

Lab Invest. 2021 Aug;101(8):1036-1047. doi: 10.1038/s41374-021-00590-w. Epub 2021 Apr 28.

Perspectives in the Treatment of or Mutated Metastatic Colorectal Cancer Patients.治疗KRAS或NRAS突变转移性结直肠癌患者的观点。

Front Oncol. 2021 Mar 2;11:602596. doi: 10.3389/fonc.2021.602596. eCollection 2021.

Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.靶向 KRAS(G12C)：从抑制机制到调节患者的抗肿瘤作用。

Cell. 2020 Nov 12;183(4):850-859. doi: 10.1016/j.cell.2020.09.044. Epub 2020 Oct 15.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验